AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29863280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26822418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with physical therapy
Number of subjects: 40
Study 26822418 — intervention group
Group type: COMPARATOR
Intervention: Placebo current combined with physical therapy
Number of subjects: 40
Study 24440678 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 F Perclose ProGlide (n = 50)
Number of subjects: 151
Study 24440678 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 F Prostar XL (n = 51)
Number of subjects: 151
Study 24440678 — intervention group
Group type: COMPARATOR
Intervention: Open femoral exposure (n = 50)
Number of subjects: 151
Study 22297243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Number of subjects: 511
Study 22297243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4mg
Number of subjects: 511
Study 22297243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 20638815 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm, empathic communication with positive expectations
Number of subjects: 30
Study 20638815 — intervention group
Group type: COMPARATOR
Intervention: Cold, formal communication with positive expectations
Number of subjects: 30
Study 20638815 — intervention group
Group type: COMPARATOR
Intervention: Warm, empathic communication with uncertain expectations
Number of subjects: 30
Study 20638815 — intervention group
Group type: COMPARATOR
Intervention: Cold, formal communication with uncertain expectations
Number of subjects: 30
Study 20638815 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm, empathic communication
Number of subjects: 30
Study 20638815 — intervention group
Group type: EXPERIMENTAL
Intervention: GP suggestions about outcomes
Number of subjects: 30
Study 18372696 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise countermeasure (LBNP-treadmill plus flywheel, EX)
Number of subjects: 24
Study 18372696 — intervention group
Group type: COMPARATOR
Intervention: No-exercise (No-EX)
Number of subjects: 24
Study 18372696 — intervention group
Group type: COMPARATOR
Intervention: No-EX
Number of subjects: 24
Study 18372696 — intervention group
Group type: EXPERIMENTAL
Intervention: EX
Number of subjects: 24
Study 15888712 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle graft
Number of subjects: 8
Study 15888712 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle graft
Number of subjects: 8
Study 12207074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) administered intravenously at a dose of 150,000 U every 12 h from the start of surgery until postoperative day 5
Number of subjects: 16
Study 12207074 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 16
Study 12207074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI)
Number of subjects: 16
Study 9445284 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal strapping
Number of subjects: 8
Study 9445284 — intervention group
Group type: COMPARATOR
Intervention: Control (no abdominal strapping)
Number of subjects: 8
Study 7979808 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (3.6 mM)
Number of subjects: 30
Study 3125794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% to 2% arachidonic acid applied under occlusion every 24 to 48 hours, five to seven times
Number of subjects: 45
Study 3125794 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic examination after treatment with arachidonic acid
Number of subjects: 45
Study 4103277 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug of anti-D gammaglobulin
Number of subjects: 844
Study 4103277 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive administration of anti-D gammaglobulin
Number of subjects: 844
Study 30917125 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS-080#22 (doses 0.08-16 mg/kg for healthy volunteers, 2-8 mg/kg for CKD patients)
Number of subjects: 72
Study 30917125 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS-080#22
Number of subjects: 72
Study 28262603 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 12 weeks
Number of subjects: 70
Study 28262603 — intervention group
Group type: COMPARATOR
Intervention: Baseline measures of AA and CRP
Number of subjects: 70
Study 28262603 — intervention group
Group type: COMPARATOR
Intervention: Baseline measures of amygdala-reactivity
Number of subjects: 70
Study 26107444 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal displacement using transesophageal echocardiography transducer
Number of subjects: 704
Study 26107444 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal displacement
Number of subjects: 704
Study 26107444 — intervention group
Group type: COMPARATOR
Intervention: No esophageal displacement (control)
Number of subjects: 704
Study 22093070 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrate supplementation at 0.5% of BW
Number of subjects: 15
Study 22093070 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrate supplementation at 1% of BW
Number of subjects: 15
Study 22093070 — intervention group
Group type: COMPARATOR
Intervention: Forage-only diet (Control)
Number of subjects: 15
Study 21355098 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 58
Study 21355098 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 58
Study 18547460 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to abstract artwork created by a member of an out-group university under baseline conditions
Number of subjects: 0
Study 18547460 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to abstract artwork created by a member of an out-group university following a manipulation of threat
Number of subjects: 0
Study 18547460 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to out-group-relevant attitude objects following a threat to identity
Number of subjects: 0
Study 18547460 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported emotion as a mediator
Number of subjects: 0
Study 16434132 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative classification as 'difficult' on the Pederson scale
Number of subjects: 105
Study 16434132 — intervention group
Group type: EXPERIMENTAL
Intervention: High Parant scores
Number of subjects: 105
Study 16434132 — intervention group
Group type: COMPARATOR
Intervention: Pederson score
Number of subjects: 105
Study 14758145 — intervention group
Group type: EXPERIMENTAL
Intervention: rPAF‐AH 1.0 mg/kg intravenously once daily for five consecutive days
Number of subjects: 1425
Study 14758145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1425
Study 11726412 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based anesthetic
Number of subjects: 60
Study 11726412 — intervention group
Group type: COMPARATOR
Intervention: Halothane-based anesthetic
Number of subjects: 60
Study 9253907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone + high-protein diet (2 g/kg/day)
Number of subjects: 23
Study 9253907 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet alone (2 g/kg/day)
Number of subjects: 23
Study 9253907 — intervention group
Group type: COMPARATOR
Intervention: Retrospective group (high-calorie, high-protein diet with 1.3 to 1.4 g/kg/day)
Number of subjects: 23
Study 8441086 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula (Prosobee)
Number of subjects: 72
Study 8441086 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula (Isomil)
Number of subjects: 72
Study 8441086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow-milk formula (Similac)
Number of subjects: 72
Study 8441086 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 72
Study 8441086 — intervention group
Group type: COMPARATOR
Intervention: All groups (HM, CBF, SBF)
Number of subjects: 72
Study 3756982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (1 mg)
Number of subjects: 9
Study 3756982 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 9
Study 31888700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maisha intervention (counseling and video session prior to HIV testing, plus two additional sessions for HIV-positive participants)
Number of subjects: 1000
Study 31888700 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 1000
Study 29862410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice (480 ml daily for 12 weeks)
Number of subjects: 37
Study 29862410 — intervention group
Group type: COMPARATOR
Intervention: Control drink (matched for energy and sugar content)
Number of subjects: 37
Study 27412869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (Orsiro)
Number of subjects: 2525
Study 27412869 — intervention group
Group type: COMPARATOR
Intervention: Biolimus-eluting stent (Nobori)
Number of subjects: 2525
Study 24718398 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care by community health workers
Number of subjects: 260
Study 24718398 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study 21882288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment for depression (psychotherapy plus antidepressants)
Number of subjects: 28
Study 21882288 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (antidepressants alone)
Number of subjects: 28
Study 19678776 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery (experimental group)
Number of subjects: 60
Study 19678776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 60
Study 19678776 — intervention group
Group type: COMPARATOR
Intervention: Control (control group)
Number of subjects: 60
Study 17475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal birth
Number of subjects: 2078
Study 17475125 — intervention group
Group type: COMPARATOR
Intervention: CS during active labour
Number of subjects: 2078
Study 17475125 — intervention group
Group type: EXPERIMENTAL
Intervention: Short active phase of the second stage of labour (< 30 minutes)
Number of subjects: 2078
Study 15183704 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual fluoroscopy for distal locking
Number of subjects: 0
Study 15183704 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual fluoroscopy for guidewire placement
Number of subjects: 0
Study 15183704 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality enhancement with 3-D cylinder model
Number of subjects: 0
Study 11579009 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 0
Study 11579009 — intervention group
Group type: COMPARATOR
Intervention: Drug-free comparison group
Number of subjects: 0
Study 7854612 — intervention group
Group type: EXPERIMENTAL
Intervention: Spill residents
Number of subjects: 350
Study 7854612 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed controls
Number of subjects: 350
Study 2638082 — intervention group
Group type: EXPERIMENTAL
Intervention: Power toothbrush with elliptical oscillating system
Number of subjects: 60
Study 2638082 — intervention group
Group type: COMPARATOR
Intervention: Power toothbrushes (various types)
Number of subjects: 60
Study 2638082 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 60
Study 2638082 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush alone
Number of subjects: 60
Study 1235771 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 6
Study 1235771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31326319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice a day for 12 weeks
Number of subjects: 347
Study 31326319 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 347
Study 31326319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib after placebo
Number of subjects: 347
Study 31326319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 347
Study 31326319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 27882439 — intervention group
Group type: EXPERIMENTAL
Intervention: MACS
Number of subjects: 237
Study 25864416 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser vaporization
Number of subjects: 229
Study 25864416 — intervention group
Group type: COMPARATOR
Intervention: TURBT (transurethral electroresection)
Number of subjects: 229
Study 23450428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat active orthosis in addition to individual exercises
Number of subjects: 52
Study 23450428 — intervention group
Group type: COMPARATOR
Intervention: Individual exercises only (Control group)
Number of subjects: 52
Study 23450428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat active orthosis
Number of subjects: 52
Study 21788316 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 95
Study 21788316 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with sedation
Number of subjects: 95
Study 19090788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with atorvastatin
Number of subjects: 100
Study 19090788 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy with pravastatin
Number of subjects: 100
Study 16720798 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant group (high perfusion correlate)
Number of subjects: 25
Study 16720798 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant group (low perfusion correlate)
Number of subjects: 25
Study 16720798 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dropouts
Number of subjects: 25
Study 16720798 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall removals
Number of subjects: 25
Study 16720798 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed participants
Number of subjects: 25
Study 15531320 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative double flap (group 1)
Number of subjects: 64
Study 15531320 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended double flap (group 2)
Number of subjects: 64
Study 15531320 — intervention group
Group type: EXPERIMENTAL
Intervention: Single flap (group 3)
Number of subjects: 64
Study 15531320 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 64
Study 11033746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation for Parenthood groups (psychosocial intervention)
Number of subjects: 187
Study 11033746 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 187
Study 11033746 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving Parenthood groups (for second‐time mothers)
Number of subjects: 187
Study 9471604 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidase measurement in blood
Number of subjects: 52
Study 9471604 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood histidase indices
Number of subjects: 52
Study 8170484 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 2.0 mg/kg alternate-day therapy
Number of subjects: 28
Study 8170484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3046332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg/kg/d)
Number of subjects: 8
Study 3046332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment initially)
Number of subjects: 8
Study 29174792 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg
Number of subjects: 12
Study 29174792 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 7.5mg/kg
Number of subjects: 12
Study 29174792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28319848 — intervention group
Group type: EXPERIMENTAL
Intervention: UC1010 (10 or 16mg) subcutaneously every second day during the luteal phase
Number of subjects: 126
Study 28319848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28319848 — intervention group
Group type: EXPERIMENTAL
Intervention: UC1010
Number of subjects: 126
Study 24695971 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 106
Study 24695971 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 106
Study 23726647 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 63
Study 23726647 — intervention group
Group type: COMPARATOR
Intervention: friendly-TSST (control)
Number of subjects: 63
Study 21569012 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused intervention (n=71)
Number of subjects: 128
Study 21569012 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-focused intervention (n=57)
Number of subjects: 128
Study 21569012 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 128
Study 18242572 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked execution of 1-key and 3-key responses
Number of subjects: 0
Study 18242572 — intervention group
Group type: COMPARATOR
Intervention: Mixed execution of 1-key and 3-key responses
Number of subjects: 0
Study 16504997 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg orally once daily for 3 days
Number of subjects: 35
Study 12898459 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) alone (50 to 75 mg, intramuscular [IM])
Number of subjects: 10
Study 12898459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Testosterone (T) and Growth Hormone (GH) treatment
Number of subjects: 10
Study 12898459 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) treatment
Number of subjects: 10
Study 10869628 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-induced thermotherapy
Number of subjects: 27
Study 9352700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg fixed dose)
Number of subjects: 98
Study 9352700 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (1-5 mg increasing doses)
Number of subjects: 98
Study 7960688 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily in the morning
Number of subjects: 203
Study 7960688 — intervention group
Group type: COMPARATOR
Intervention: 300 mg ranitidine once daily at night
Number of subjects: 203
Study 3506627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress test with high stimulus intensity
Number of subjects: 0
Study 3506627 — intervention group
Group type: COMPARATOR
Intervention: Mental stress test with low stimulus intensity
Number of subjects: 0
Study 31325124 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized polychromatic light (40 mW/cm2, wavelengths 480-3400 nm)
Number of subjects: 36
Study 31325124 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous LED light (16 mW/cm2, wavelengths 625, 660, 850 nm)
Number of subjects: 36
Study 31325124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed LED light
Number of subjects: 36
Study 31325124 — intervention group
Group type: COMPARATOR
Intervention: Non-therapeutic visible light (control)
Number of subjects: 36
Study 29108938 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine inhaled corticosteroids (QVAR 80 μg, two puffs twice per day, equivalent to 800 μg per day beclomethasone dipropionate)
Number of subjects: 214
Study 29108938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 26711958 — intervention group
Group type: EXPERIMENTAL
Intervention: TRANSFoRm tools for recruitment and follow-up
Number of subjects: 15
Study 26711958 — intervention group
Group type: EXPERIMENTAL
Intervention: TRANSFoRm apps for reporting patient outcomes
Number of subjects: 15
Study 26711958 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of TRANSFoRm tools
Number of subjects: 15
Study 25202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 735
Study 25202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 735
Study 23431202 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of stimulus statistics
Number of subjects: 0
Study 20456291 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (40 mg/kg or 60 mg/kg)
Number of subjects: 10
Study 20456291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.7 g/kg)
Number of subjects: 10
Study 20456291 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.25 mg)
Number of subjects: 10
Study 20456291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18158634 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured box model training curriculum
Number of subjects: 16
Study 18158634 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 16647412 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanols (2.0 g daily in low-fat yogurt)
Number of subjects: 42
Study 16647412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-fat yogurt)
Number of subjects: 42
Study 12732777 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaSure (37 women)
Number of subjects: 67
Study 12732777 — intervention group
Group type: COMPARATOR
Intervention: ThermaChoice (30 women)
Number of subjects: 67
Study 10793592 — intervention group
Group type: EXPERIMENTAL
Intervention: MIKE (ketamine 3 mg kg‐1, midazolam 0.5 mg kg‐1)
Number of subjects: 120
Study 10793592 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg kg‐1)
Number of subjects: 120
Study 10793592 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (6 mg kg‐1)
Number of subjects: 120
Study 8616591 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.05 ml/kg to 1.0 ml/kg body weight)
Number of subjects: 0
Study 8616591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1431767 — intervention group
Group type: EXPERIMENTAL
Intervention: Particles-in-tablet form of erythromycin (333 mg three times daily for 10 days)
Number of subjects: 0
Study 1431767 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate (400 mg four times daily for 10 days)
Number of subjects: 0
Study 3888133 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual plus feedback group
Number of subjects: 56
Study 3888133 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual group
Number of subjects: 56